Validation of Mild Cognitive Impairment in Parkinson's Disease (MCI) Study Group

Gert J. Geurtsen Jennifer G. Goldman Alex Tröster
Chair: Gert J. Geurtsen Vice Chair: Jennifer G. Goldman Vice Chair: Alexander I. Tröster


MDS Staff Liaison: Ken Buesing



  • Director, Cleveland Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, OH (Dr. James B. Leverenz)
  • Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois (Dr. Jennifer G. Goldman);
  • Barrow Neurological Institute, Phoenix, AZ (Dr. Alexander I. Troster);
  • San Diego Medical Center and Department of Neurosciences University of California, San Diego, CA (Dr. J. Vincent Filoteo and Dr. Irene Litvan)
  • Departments of Psychiatry and Neurology and Parkinson’s Disease and Mental Illness Research, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA (Dr. Daniel Weintraub);
  • Arizona Parkinson’s Disease Consortium, Mayo Clinic Arizona, Scottsdale, AZ and Banner Sun Health Research Institute, Sun City, AZ (Dr. Charles H. Adler, Dr. Sandra Jacobson, and Dr. John Caviness);
  • Department of Neurology, University of Washington School of Medicine, Seattle, WA (Dr. Cyrus P. Zabetian and Dr. Brenda A. Cholerton);
  • Department of Neurology, Hershey Medical Center (Dr. Xuemei Huang and Dr. Paul Eslinger)


  • Movement disorders centre and Safra program in Parkinson’s research, Toronto Western Hospital (Dr. Connie Marras and Dr. Sarah Duff-Canning);The Centre for Applied Neurogenetics, University of British Columbia (Dr. Matt Farrer)

New Zealand

  • New Zealand Brain Research Institute, Christchurch (Dr. John C. Dalrymple-Alford and Dr. Tim J. Anderson)


  • Brain & Mind Research Institute, The University of Sydney (Dr. Sharon L. Naismith, Dr. Simon JG Lewis and Dr. Glenda M. Halliday)


  • Department of Neurology and Psychology, National Taiwan University Hospital, Taipei (Dr. R.M Wu);
  • Institute of Behavioral Medicine, National Cheng Kung University, Tainan (Dr. R.L. Yu)

United Kingdom

  • Cambridge Center for Brain Repair, University of Cambridge (Dr. Caroline H. Williams-Gray, Dr. David P. Breen and Dr. Roger A. Barker);
  • Institute for Aging and Health, Newcastle University (Dr. David J. Burn and Dr Alison J. Yarnall)

The Netherlands

  • Department of Neurology, AMC and University of Amsterdam (Dr. Ben A. Schmand and Dr. Rob M.A. de Bie);
  • VU Neurology department (Ted Koene Msc and Dr. Martin Klein)


  • Paracelsus-Elena-Klinik, Kassel, and Georg-August University Goettingen (Dr. Brit Mollenhauer and Dr.  Ellen Trautmann);
  • Dempark; Department of Neurology, Philipps University Marburg, Marburg, Germany (Dr. R. Dodel)


  • Movement Disorders Unit, Neurology Department, Hospital and Institute of Biomedical Research Sant Pau, Barcelona (Dr. Jaime Kulisevsky and Dr. Javier Pagonabaragga);
  • Department of Neurology, Hospital Donostia, Donostia, San Sebatian and Ikerbasque, Basque Foundation for Science, Bilbao (Dr. Maria C. Rodriguez-Oroz and Dr. Carmen Gasca-Salas)
  • Department of psychiatry and Psychobiology clínic, Faculty of Medicin, University of Barcelona, Spain (Dr. Carme Junqué and Dr. Barbara Segura)


  • Neurogenerative disease centre, University of Salerno (Dr. Paolo Barone and Dr. Gabriella Santangelo);
  • Department of Surgery, Medical, Molecular, and Critical Area Pathology, University School of Medicine, Pisa (Dr. Marco Timpano Sportiello and Dr. Davide M Cammisuli);
  • Parkinson Unit, Fondazione Ospedale San Camillo IRCCS, Venice (Dr. Roberta Biundo)


  • Parkwest study (Dr. Kenn Freddy Pedersen and Dr. Guido Alves)
Steering Committee

Steering Committee: Irene Litvan, Ben A. Schmand, Alexander I. Tröster, Jennifer G. Goldman and David J. Burn


1. Validation of the MDS PD-MCI criteria

  • comparison of the two levels of criteria (abbreviated assessment {I} versus comprehensive assessment {II}) in their ability to detect PD-MCI and predict conversion to dementia
  • applicability of the criteria

2. Definition of best cut-off score

  • to discriminate patient with and without PD-MCI
  • to predict conversion to dementia

3. Generating epidemiologic data by:

  • defining the prevalence of PD-MCI
  • comparing the prevalence across different sites/cohort types
  • defining the prevalence of the different subtypes of PD-MCI

4. Determine relationship PD-MCI, mood and Quality of Life

  • analyzing mood and Quality of Life in no-PD-MCI, PD-MCI and PDD groups
Additional Information

The 24 international sites have PD cohorts that are being combined. These cohorts include ≥ 3,600 PD patients and ≥ 1,500 controls to validate level I in ≥ 2,100 patients whom 82% participate in longitudinal studies and ≥ 1,500 patients to validate level II. Just over 640 (43%) of those level II patients are followed longitudinally. Two PhD student have started October 2013 and the planned duration of the validation project is two years.

An overview of the research plans has been published in the Journal of Parkinson's Disease, posters have been presented at the MDS International Congress in Stockholm and San Diego and a presentation was given at NMDPD in Nice, France, and at the MDS 20th International Congress in San Diego, CA, USA.


Michael J. Fox Foundation (Dr. Jamie Eberling)
Parkinson Vereniging (Dutch Parkinson Association)
University of Amsterdam, psychology department


Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Trőster AI, Burn DJ, Litvan  I. Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. J Parkinsons Dis. 2014; 4(2); 131-137.


We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice